Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review highlights the efficacy of transdermal testosterone therapy in improving sexual function in women with hypoactive sexual desire disorder, though approved formulations and long-term safety data are limited.

This study found that finasteride use for androgenetic alopecia was not associated with increased sexual dysfunction compared to an age-matched control group.

This study found that women with nonclassic congenital adrenal hyperplasia (NC-CAH) reported lower sexual function and higher sexual distress compared to those with classic CAH (C-CAH), particularly among those showing signs of androgen excess.

This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.

This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.

This review discusses the neurobiology of sexual function and reports no new results; the authors cover multiple endocrine and neurotransmitter influences on sexual desire, arousal, and orgasm stages.

This narrative review discusses the impact of polycystic ovary syndrome on women's psychological and sexual well-being, highlighting the potential benefits of interdisciplinary treatments and new interventions to improve life satisfaction and coping, but reports no new results.

In a randomized study, men treated with dutasteride for androgenetic alopecia experienced sexual adverse events at twice the rate of those on placebo during 24 weeks, but these events were mild, moderate, and resolved after treatment.

In this study, 50 mg/day of DHEA supplementation in postmenopausal women did not significantly improve sexual function compared to a placebo over 26 weeks.

This review examines the sexual side effects of 5α-reductase inhibitors like finasteride, highlighting the increased risk of erectile dysfunction, libido reduction, and potential contribution to depression without new clinical findings.

This review concluded that for women, the benefits of testosterone implants are outweighed by risks, with possible higher rates of irreversible adverse effects than previously reported.

This case report describes a 46-year-old Italian woman with congenital adrenal hyperplasia who experienced significant improvements in physical and psychological health after receiving a delayed diagnosis and subsequent treatment.

This study found no evidence of androgen deficiency or decreased peripheral androgen action in men with persistent sexual symptoms after finasteride use, but identified links to depressed mood and abnormal brain function.

This study found no significant relationship between hormone levels and sexual function in hirsute young women compared to a control group.

This study found no clear evidence that finasteride negatively affects erectile function, though it does cause a reduction in ejaculatory volume and has potential implications for prostate cancer risk.

This study observed that lifestyle modifications resulting in weight loss improved menstrual irregularity and hormonal balance among infertile obese women with polycystic ovary syndrome, although changes in total testosterone and estrone were not significant.

Norplant implants lower some androgen levels but don't significantly change sexual function.

This study found that lower urinary tract symptoms in older men with benign prostatic hyperplasia negatively impact sexual function and mental health, suggesting the importance of early intervention to improve quality of life.

Testosterone replacement can help menopausal women with various symptoms, but should be used carefully and is not yet officially licensed in the UK for women.

This review examines the impact of spontaneous premature ovarian insufficiency on women's sexual function and highlights the need for a comprehensive, biopsychosocial approach to management, but presents no new clinical results.

This review discusses the impact of testosterone therapy on postmenopausal women's sexual function and well-being but notes a lack of long-term safety studies and debates on defining androgen insufficiency.

This article reviews the use of cross-sex hormonal therapy in transmen and reports that it is reasonably safe, suggesting monitoring should be frequent initially but can be less frequent over time.

This review examines age-related changes in androgen levels in women and explores the rationale for testosterone replacement therapy, but it reports no new clinical findings.

This review discusses the role of androgens in women's sexual health and highlights the need for further research on androgen replacement therapy to optimize quality of life, but reports no new clinical results.

This review discusses the changes in androgen levels with age in women and the potential benefits of testosterone replacement therapy as part of hormone replacement therapy for postmenopausal women, but it reports no new clinical results.

This study suggests that sexual dimorphism in adipose tissue functions may be linked to androgen levels, as women with PCOS demonstrated a more masculine adipokine expression pattern.

Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.

This review discusses guidelines for androgen use in women and concludes that more research is needed before recommending testosterone due to insufficient evidence on safety and efficacy.

In this study, men with previous finasteride use reported more severe sexual and psychological symptoms with greater cumulative exposure and older age, highlighting a need for further research on risk factors and long-term impacts.